Evidence map›Paper›PMID 18533806›Full record

ReviewExpert review of anticancer therapy2008

Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.

T J Fitzgerald, Tao Wang, Hira Lal Goel, Jiayi Huang, Gary Stein, Jane Lian, Roger J Davis, Steven Doxsey, K C Balaji, Jesse Aronowitz and 1 more

Abstract readReview
In one paragraph

Review in Expert review of anticancer therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Cancers · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Human Prostate Cancer Hallmarks Map.Scientific reports · 2016
    Article
  13. Review
  14. Article
  15. Review
  16. Prostate cancer regulatory networks.Journal of cellular biochemistry · 2009
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

T J FitzgeraldDepartment of Radiation Oncology, University of Massachusetts Medical School, 55 Lake Avenue North Worcester, MA 01605, USA. fitzgert@ummhc.org
Tao Wang
Hira Lal Goel
Jiayi Huang
Gary Stein
Jane Lian
Roger J Davis
Steven Doxsey
K C Balaji
Jesse Aronowitz
Lucia R Languino

Funding

INTEGRIN SIGNALING PATHWAYS IN PROSTATE CANCERR01CA089720 · NCI · YALE UNIVERSITY · PI LANGUINO, LUCIA R. · 2001 to 2014
$2.8M
Beta1 Integrins and IGF-l Receptor in Prostate CancerR01CA109874 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANGUINO, LUCIA R. · 2005 to 2015
$2.7M
NCI NIH HHS R01 CA089720NCI NIH HHS R01 CA-109874NCI NIH HHS R01 CA109874NCI NIH HHS R01 CA-89720
6 · The paper itself

Abstract

Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.

Indexed as

AdenocarcinomaHumansMaleNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsRadiation ToleranceRisk FactorsTreatment OutcomeProstate-Specific Antigen

Identifiers

PMID18533806
PMCPMC2764989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.